A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
This study is testing an experimental medication called ABN401, sometimes given with lazertinib, to see how well it treats advanced lung cancer. It is designed for patients whose cancer has a specific genetic change known as MET exon 14 skipping.
You may be able to join if you are 18 or older, can do your normal daily activities, and have advanced non-small cell lung cancer with the specific MET genetic mutation confirmed by a test. However, you cannot join if you have already received prior chemotherapy or other treatments targeting c-MET.
Participants will receive the study medication and be closely monitored by the medical team to check safety, side effects, and how the drug works in the body. Regular check-ups and tests will be part of your care throughout the study.
The study is currently active and recruiting participants at locations in Lake City and Orange City, Florida, as well as Detroit, Michigan.
- 1Testing an experimental targeted cancer medication called ABN401.
- 2For adults with advanced non-small cell lung cancer and a specific MET genetic mutation.
- 3Currently recruiting patients at study sites in Florida and Michigan.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.